All News
Dr. Takuya Miyazaki (CEO) gives a pitch presentation at the PITCH GLOBAL (Virtual)
08/17/2022. Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. will give a pitch presentation in front of Sr SF Investors @UC Berkeley at the PITCH GLOBAL event on August 20 (via Zoom).
Dr. Takuya Miyazaki (CEO) gives a pitch presentation at the Pitch to CVC’s/VC’s’ angels +TDK&SK Group Thought Leadership. (Virtual)
08/12/2022. Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. gave a pitch presentation at the Pitch to CVC’s/VC’s’ angels +TDK&SK Group Thought Leadership that organized by the PITCH GLOBAL (www.pitchglobal.com).
Dr. Takuya Miyazaki (CEO) attends the 2022 Venture Summit West in Silicon Valley, CA
19/07/2022. Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. attended the Venture Summit West from July 19-20, 2022, in Silicon Valley, CA. We look forward to meeting with top innovators and investors there.
Red Arrow Therapeutics, Co. Ltd. presents promising preclinical data of RA-001 at ACCR Annual Meeting 2022
08/04/2022 Prof. Horacio Cabral from Red Arrow Therapeutics, Co., Ltd. presented promising preclinical data of RA-001 (pH-sensitive polymeric micelles loading IL-12) at AACR Annual Meeting 2022. RA-001 demonstrated a potent anti-tumor immunity in multiple tumor models. Furthermore, RA-001 showed high efficacy as monotherapy and in combination with immune checkpoint inhibitors.
Dr. Takuya Miyazaki (CEO) joins a pitch event powered by CIC/LINK-J
06/03/2022 Dr. Takuya Miyazaki, CEO from Red Arrow Therapeutics, Co. Ltd. joined a pitch event, namely, STEP to Biotech/Healthcare Startups powered by CIC/LINK-J. He performed two presentations to spread a company overview and to look for talented persons.
Red Arrow Therapeutics, Co. Ltd. develops a pipeline by using AMED grant.
09/02/2022 Red Arrow Therapeutics, Co. Ltd. will develop a pipeline by using AMED Seeds A grant. We aim to make proceedings on lead optimization by using this grant.
Red Arrow Therapeutics, Co. Ltd. closes their 1st seed round
15/12/2021 Red Arrow Therapeutics, Co. Ltd. closed their 1st seed round. They earned 0.8 M USD to develop their pipeline, IP and HR. They will look for additional fundings to earn 0.2-0.4 M USD by April.